Peter W. PENG, Author at MediaMedic

WCLC 2023 | Dr. Han Baohui’s Team Presents Multiple Research Achievements, Making China’s Voice Resonate at WCLC

By Peter W. PENG 2024.01.19

The 2023 World Conference on Lung Cancer (WCLC) was held at the Singapore Expo, attracted over 6,000 participants from various fields of basic and clinical science related to thoracic malignancies. The conference received approximately 1,800 abstracts, featured over 350 invited lectures, 150 oral presentations, mini-oral presentations, and more than 1,500 posters and electronic posters, showcased the latest advancements in the field of thoracic oncology. At the WCLC conference, " Oncology Frontier" invited Dr. Han Baohui, Zhong Runbo, Zhang Wei, and Lu Jun from the affiliated Thoracic Hospital of Shanghai Jiao Tong University School of Medicine to engage in discussions on hot topics at the conference and important clinical research.

WCLC 2023 | Dr. Ramalingam Shares Wining Statement as a Winner of the IASLC Scientific Award

By Peter W. PENG 2024.01.19

The Paul A. Bunn, Jr. Scientific Award, bestowed by IASLC, aims to honor the lifelong scientific contributions of IASLC scientists to thoracic cancer research. Dr. Ramalingam's research focuses on developing new treatment strategies for lung cancer patients. His team developed innovative treatment regimens for lung cancer patients with EGFR mutations, which led to the FDA's approval of a third-generation EGFR inhibitor for metastatic non-small cell lung cancer. Additionally He also led clinical and translational research on new immunotherapies for treating lung cancer , resulting in over 400 published, peer-reviewed publications. He also served on the IASLC board of directors (2017-2021) and the NCI Thoracic Malignancy Steering Committee (2012-2021). He is currently the chief editor of the journal 《Cancer》 published by the American Society of Clinical Oncology.

ILTS 2023｜Shifting Paradigms in Radiological Assessment of Tumor Load in Liver Transplantation for HCC

By Peter W. PENG 2024.01.18

Liver transplantation is a crucial option for treating Hepatocellular Carcinoma (HCC) as it not only removes the tumor but also addresses underlying liver disease. Accurate prediction of post-transplantation outcomes for patients with HCC tumors exceeding MELD standards or awaiting transplantation due to donor shortages is essential to enhance surgical success rates and optimize liver allocation. At the International Liver Transplantation Society (ILTS) Annual Meeting held in Rotterdam, the Netherlands, from May 3rd to 6th, 2023, Dr. Leonardo Centonze from Niguarda Hospital in Milan, Italy, presented a recent clinical study. The study suggests that dynamic grading based on the Liver Imaging Reporting and Data System (LI-RADS) has a significant impact on preoperative outcome prediction. The research indicates that for HCC patients with multiple nodules, every nodule in the liver (not just highly suspicious lesions) should be considered for preoperative evaluation. This will influence the accuracy of liver transplantation outcome prediction.

ILTS 2023 | New Approach for Early Detection of Hepatocellular Carcinoma – Biophysical Characteristics of Tumor Tissue and Serum

By Peter W. PENG 2024.01.18

Biological physics is an interdisciplinary field that combines physics with biology, serving as an important branch of both life sciences and physics. Its aim is to elucidate the laws governing the motion of matter, energy, and information in biological systems within specific spatial and temporal contexts. However, the potential role of biophysical techniques in early cancer screening, particularly for liver cancer, remains a burgeoning research area with limited reports. At the International Liver Transplantation Society (ILTS) Annual Meeting held in Rotterdam, the Netherlands from May 3rd to 6th, 2023, Dr. Subathra Radhakrishnan from the Indian National Liver Foundation presented a study that suggests biophysical analysis may offer new means for non-invasive early diagnosis of Hepatocellular Carcinoma.

Dr. Huichuan Sun: Focusing on the Asia-Pacific Region, Leading the Frontier – Exploring Breakthroughs in the Treatment of Hepatobiliary Tumor

By Peter W. PENG 2024.01.17

The 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023) recently concluded in Seoul, South Korea, bringing together top experts in liver and biliary system tumors from around the world to discuss clinical hot topics and challenges. Dr. Huichuan Sun from Zhongshan Hospital, Fudan University, China, shares and interprets the latest developments and frontiers, including the Asia-Pacific consensus and groundbreaking research with us.

Dr. Huiqiang Huang: Just around the corner! Extranodal NK/T-cell lymphoma is ushering in the era of immunotherapy.

By Peter W. PENG 2024.01.16

Extranodal NK/T-cell lymphoma (ENKTCL) of nasal type is a rare subtype, commonly found in the Asian population and associated with the Epstein-Barr Virus (EBV). At present, the prognosis for patients remains poor, especially for relapsed/refractory (R/R) cases. From June 8 to 11, 2023, the 28th European Hematology Association (EHA) annual meeting was held in Frankfurt, Germany. A selected oral report (Abstract No.: S226) from the conference showed that the use of PD-1 inhibitors alone or in combination significantly improved the treatment of R/R ENKTCL patients. This study further confirmed that immune checkpoint inhibitors have become an important treatment option for R/R ENKTCL patients. Oncology Frontier invited Dr. Huiqiang Huang from Sun Yat-sen University Cancer Center to share the research findings and insights at the conference.

Dr. Zhengfei Zhu: Can EGFR-TKI Combined with Local Consolidative Therapy Achieve “1+1＞2”?

By Peter W. PENG 2024.01.15

The 2023 European Lung Cancer Congress (ELCC) is taking place in Copenhagen, the capital of the fairy tale kingdom of Denmark. On the first day of the conference, a session of oral presentations showcased the Phase II randomized study data on EGFR-TKI combined with local consolidative therapy for treating EGFR mutant metastatic non-small cell lung cancer (NSCLC) . Dr. Zhengfei Zhu from Fudan University Affiliated Tumor Hospital provides commentary on these research findings.

Dr. Hui Wang: A Simple and Rapid Multi-Parameter Flow Cytometry Approach for the Diagnosis and Screening of Malignant Tumors and Related Diseases

By Peter W. PENG 2024.01.15

From June 8 to 12, 2023, the 28th European Hematology Association (EHA) Congress will be held in Frankfurt, Germany, bringing together experts and scholars from around the world to present exciting advances in research. In the field of hematology testing, multi-parameter flow cytometry (MFC) is an important clinical diagnostic method, and the development of fast, simple, and efficient protocols is essential for this technology. A real-world study (P588) conducted by Dr. Hui Wang's team from Hebei Yanda Ludaopei Hospital and Beijing Ludaopei Hospital has been selected for presentation at EHA. The study aims to introduce the research achievements of Ludaopei Hospital over the years: a rapid, simple, and efficient MFC test for screening and diagnosing malignant tumors and related diseases. To gain a deeper understanding of this research, "Oncology Insight" invited Professor Wang Hui to provide a detailed analysis, which is summarized below.

Dr. Niels Van de Donk Interprets the Latest Research Progress on CAR-T Treatment for RRMM

By Peter W. PENG 2024.01.15

From June 8th to 11th, 2023, the 28th European Hematology Association (EHA) was held in Frankfurt, Germany, both online and offline. The conference was hosted by the European Hematology Association. As the largest international conference in the European hematology field, it attracts over 10,000 professionals from more than 100 countries each year to share and discuss innovative concepts and the latest scientific and clinical research results in hematology. At the EHA conference site, Oncology Frontier specially invited Professor Niels Van de Donk from Amsterdam University Medical Center (AMC-UvA) to interpret the latest research and future direction of CAR-T in the treatment of relapsed/refractory multiple myeloma (RRMM)

Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

By Peter W. PENG 2024.01.15

Dr. Iskandar Azwa Chairman of the Malaysian AIDS Council, Head of Infectious Diseases Department at the University of Malaya Medical Center. His research interests include pre-exposure prophylaxis (PrEP) implementation in key populations, HIV drug resistance, and evaluating new HIV treatment strategies. He is the principal investigator for several international collaborative HIV clinical trials, including TAHOD, START, and D2EFT studies. At the APACC 2023 conference, Dr. Iskandar Azwa delivered an insightful presentation on "The Role of Nucleosides in Second-Line HIV Treatment." Our journal had the privilege to conduct an in-depth interview with Dr. Azwa regarding the choices for second and third-line treatment for HIV/AIDS patients.